Accuracy of Various Human NAT2 SNP Genotyping Panels to Infer Rapid, Intermediate and Slow Acetylator Phenotypes

10.1136/bmj.2.5197.485

Weber WW , HeinDW. N-acetylation pharmacogenetics. Pharmacol. Rev.37 , 25–79 (1985).

10.1081/DMR-100101932

10.1073/pnas.88.12.5237

10.1073/pnas.88.14.6333

10.1080/03602530500251204

10.1159/000028402

10.1016/j.tox.2008.08.022

Hein DW , DollMA, FretlandAJ et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9 , 29–42 (2000).

10.2174/138920008784892083

10.2174/138920008784892065

10.1517/17425250902877698

10.1158/1055-9965.1543.13.9

10.1006/abio.1995.9978

10.1038/ng.687

10.1097/FPC.0b013e32833e1b54

10.1124/jpet.110.168567

10.1006/abio.2000.4892

10.1038/sj.onc.1209374

Leff MA , EpsteinPN, DollMA et al. Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J. Pharmacol. Exp. Ther. 290 , 182–187 (1999).

10.1038/clpt.1980.16

10.1007/s00228-006-0110-6

10.1016/S0021-9258(19)38219-5

10.1164/ajrccm.155.5.9154882

10.1136/jmg.34.9.758

10.1128/AAC.49.5.1733-1738.2005

10.1016/j.cca.2009.06.025

10.1111/j.1365-2125.1984.tb02372.x

10.1002/ajmg.1320570413

Hein DW , TrinidadA, YerokunT, FergusonRJ, KirlinWG, WeberWW. Genetic control of acetyl coenzyme A-dependent arylamine N-acetyltransferase, hydrazine N-acetyltransferase, and N-hydroxy-arylamine O-acetyltransferase enzymes in C57BL/6J, A/J, AC57F1, and the rapid and slow acetylator A.B6 and B6.A congenic inbred mouse. Drug Metab. Dispos.16 , 341–347 (1988).

Hein DW , RustanTD, BucherKD, MillerLS. Polymorphic and monomorphic expression of arylamine carcinogen N-acetyltransferase isozymes in tumor target organ cytosols of Syrian-hamsters congenic at the polymorphic acetyltransferase locus. J. Pharmacol. Exp. Ther.259 , 699–704 (1991).

10.1006/taap.1994.1003

Hein DW , RustanTD, BucherKD, MartinWJ, FurmanEJ. Acetylator phenotype-dependent and -independent expression of arylamine N-acetyltransferase isozymes in rapid and slow acetylator inbred rat liver. Drug Metab. Dispos.19 , 933–937 (1991).

10.1124/dmd.108.023960

Grant DM , BlumM, BeerM, MeyerUA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol.39 , 184–191 (1991).

10.1093/carcin/14.8.1633

10.1093/hmg/3.5.729

Hein DW , DollMA, RustanTD, FergusonRJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res.55 , 3531–3536 (1995).

10.1016/S0027-5107(97)00026-2

10.1097/00008571-200104000-00004

10.1002/ijc.21957

10.1097/00008571-200411000-00002

10.1093/carcin/bgm085

10.1097/FPC.0b013e3283493a23

10.1016/S0361-090X(02)00010-7

10.1186/1471-2156-9-21

10.1371/journal.pone.0018507

Ohno M , YamaguchiI, YamamotoI et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 4 , 256–261 (2000).

10.2133/dmpk.17.357

10.1016/j.tube.2007.05.012

10.1038/nature09270

University of Louisville KY USA. Department of pharmacology and toxicology. www.n-acetyltransferasenomenclature.louisville.edu

Celsis. Characterization tables. www.celsis.com/ivt/characterization-tables/

US Census Burea. Overview of race and Hispanic origin: 2010. www.census.gov/prod/cen2010/briefs/c2010br-02.pdf